Oct 24 2016
Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, and ION Solutions, a part of AmerisourceBergen, and the largest physician services organization specializing in the support of community oncology, announced today that they have entered into a relationship to deliver quality hereditary cancer test results and services to ION member practices. Through this relationship, Myriad and ION will work together to enhance the operational and clinical value associated with hereditary cancer testing. Myriad will be ION’s preferred partner for hereditary cancer testing focused on bringing specialized tests and services to meet the specific needs of community oncology practices. This partnership will advance the organizations’ shared goals of providing accurate and comprehensive hereditary cancer test results and service to community oncologists and their patients.
“Myriad has demonstrated its commitment to quality with its significant investments in research, laboratory processes, variant interpretation and exceptional customer service,” said Mark Santos, RPh, president of ION GPO. “This relationship supports ION Solutions in making important genetic tests available to our members in a way that will help inform treatment decisions and build patient care plans in the context of specific practice processes and objectives.”
"ION Solutions is the industry leader in bringing effective business and clinical solutions to the largest segment of community oncology practices in the nation.” said Alexander Ford, president of Myriad Genetic Laboratories, Inc. "Our focus as a company is on providing accurate, affordable and clinically significant genetic test results to providers and the patients they care for. We believe we share this commitment with ION Solutions and their members, and that through this partnership, the largest, most innovative private practices in the country will gain enhanced access to our services.”
Glucose-fructose mix found in sugary drinks fuels colorectal cancer metastasis